Fort Worth is moving to curb rapid growth in city employee healthcare costs, which are largely driven by growing prescriptions for GLP-1 weight loss drugs such as Ozempic, Wegovy and Zepbound.
One proposed change the city is considering would limit coverage of Ozempic to when it is physician-prescribed as a medication for diabetes, but eliminate coverage of Wegovy and Zepbound prescribed for cosmetic weight loss.
“What we’re dealing with is a structural issue with how we are funding our health plan,” Jay Chapa, city manager, said during a recent city council work session on the fiscal 2027 budget. “A big part of it is prescriptions.”…